2 results
Approved WMOCompleted
The primary objective of the study is:* To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab 15 mg/kg intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial…
Approved WMOCompleted
Three cohorts will be included consisting of subjects with biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and all other solid tumorhistologies not included in Cohorts 1-2 such as NSCLC, head and neck cancer, thyroid cancer, oral…